Globe News Wire · October 29, 2026

OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

Get the app for more

Explore stock news, insights and company research.